LAS VEGAS, NV--(Marketwired - Jul 20, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company") an early development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes is pleased to update the timeline of its previously announced clinical trials regarding its innovative and proprietary technology branded under the trade name e-Balance. Dr. John Sanderson, Cell MedX Chief Medical Officer, has commenced the following program, which aims to accurately measure and quantify eBalance's ability to alter key metabolic pathways targeting improved blood sugar control in patients living with diabetes....
↧